These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33750129)

  • 1. Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions.
    Jirkovská A; Karabanovich G; Kubeš J; Skalická V; Melnikova I; Korábečný J; Kučera T; Jirkovský E; Nováková L; Bavlovič Piskáčková H; Škoda J; Štěrba M; Austin CA; Šimůnek T; Roh J
    J Med Chem; 2021 Apr; 64(7):3997-4019. PubMed ID: 33750129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
    Kollárová-Brázdová P; Jirkovská A; Karabanovich G; Pokorná Z; Bavlovič Piskáčková H; Jirkovský E; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Skalická V; Štěrbová-Kovaříková P; Roh J; Šimůnek T; Štěrba M
    J Pharmacol Exp Ther; 2020 Jun; 373(3):402-415. PubMed ID: 32253261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.
    Bures J; Jirkovska A; Sestak V; Jansova H; Karabanovich G; Roh J; Sterba M; Simunek T; Kovarikova P
    Toxicology; 2017 Dec; 392():1-10. PubMed ID: 28941780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
    Bavlovič Piskáčková H; Jansová H; Kubeš J; Karabanovich G; Váňová N; Kollárová-Brázdová P; Melnikova I; Jirkovská A; Lenčová-Popelová O; Chládek J; Roh J; Šimůnek T; Štěrba M; Štěrbová-Kovaříková P
    Sci Rep; 2021 Feb; 11(1):4456. PubMed ID: 33627707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
    Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
    Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo.
    Kollárová-Brázdová P; Lenčová-Popelová O; Karabanovich G; Kocúrová-Lengvarská J; Kubeš J; Váňová N; Mazurová Y; Adamcová M; Jirkovská A; Holečková M; Šimůnek T; Štěrbová-Kovaříková P; Roh J; Štěrba M
    Clin Sci (Lond); 2021 Aug; 135(15):1897-1914. PubMed ID: 34318878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
    Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
    PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
    Hasinoff BB; Patel D; Wu X
    Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
    Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
    BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage.
    Keresteš V; Kubeš J; Applová L; Kollárová P; Lenčová-Popelová O; Melnikova I; Karabanovich G; Khazeem MM; Bavlovič-Piskáčková H; Štěrbová-Kovaříková P; Austin CA; Roh J; Štěrba M; Šimůnek T; Jirkovská A
    Toxicol Sci; 2024 Mar; 198(2):288-302. PubMed ID: 38290791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane.
    Hasinoff BB; Patel D; Wu X
    Cardiovasc Toxicol; 2020 Jun; 20(3):312-320. PubMed ID: 31773441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
    Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
    J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
    Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
    Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.
    Popelová O; Sterba M; Hasková P; Simůnek T; Hroch M; Guncová I; Nachtigal P; Adamcová M; Gersl V; Mazurová Y
    Br J Cancer; 2009 Sep; 101(5):792-802. PubMed ID: 19623174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
    Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
    Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.
    Stěrba M; Popelová O; Vávrová A; Jirkovský E; Kovaříková P; Geršl V; Simůnek T
    Antioxid Redox Signal; 2013 Mar; 18(8):899-929. PubMed ID: 22794198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II.
    Hasinoff BB; Kuschak TI; Fattman CL; Yalowich JC
    Anticancer Drugs; 1998 Jun; 9(5):465-71. PubMed ID: 9660545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexrazoxane (ICRF-187).
    Weiss G; Loyevsky M; Gordeuk VR
    Gen Pharmacol; 1999 Jan; 32(1):155-8. PubMed ID: 9888268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).
    Hasinoff BB; Kuschak TI; Yalowich JC; Creighton AM
    Biochem Pharmacol; 1995 Sep; 50(7):953-8. PubMed ID: 7575679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.